Construction of Salmonella typhimurium YG7108 strains, each coexpressing a form of human cytochrome P450 with NADPH–cytochrome P450 reductase
Ken-ichi Fujita
Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Search for more papers by this authorKazuo Nakayama
Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Search for more papers by this authorYoshiyuki Yamazaki
Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Search for more papers by this authorKazuhiro Tsuruma
Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Search for more papers by this authorMasami Yamada
Division of Genetics and Mutagenesis, National Institute of Health Sciences, Tokyo, Japan
Search for more papers by this authorTakehiko Nohmi
Division of Genetics and Mutagenesis, National Institute of Health Sciences, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Tetsuya Kamataki
Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita-ku N12W6, Sapporo 060-0812, JapanSearch for more papers by this authorKen-ichi Fujita
Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Search for more papers by this authorKazuo Nakayama
Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Search for more papers by this authorYoshiyuki Yamazaki
Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Search for more papers by this authorKazuhiro Tsuruma
Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Search for more papers by this authorMasami Yamada
Division of Genetics and Mutagenesis, National Institute of Health Sciences, Tokyo, Japan
Search for more papers by this authorTakehiko Nohmi
Division of Genetics and Mutagenesis, National Institute of Health Sciences, Tokyo, Japan
Search for more papers by this authorCorresponding Author
Tetsuya Kamataki
Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan
Laboratory of Drug Metabolism, Graduate School of Pharmaceutical Sciences, Hokkaido University, Kita-ku N12W6, Sapporo 060-0812, JapanSearch for more papers by this authorAbstract
A series of Salmonella typhimurium (S. typhimurium) YG7108 strains, each coexpressing a form of human cytochrome P450 (CYP) (CYP1A1, CYP1A2, CYP1B1, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, or CYP3A5) together with human NADPH–cytochrome P450 reductase (OR), was established. The parental S. typhimurium YG7108, derived from TA1535, lacks two O6-methylguanine-DNA methyltransferase genes, ada and ogt, and is highly sensitive to the mutagenicity of alkylating agents. The expression levels of CYP holo-protein in the genetically engineered S. typhimurium YG7108 cells, determined by carbon monoxide (CO) difference spectra, ranged from 62 nmol/L culture for CYP2C19 to 169 nmol/L culture for CYP3A4. The expression level of the OR varied, depending on the form of CYP coexpressed, and ranged from 214 to 1029 units/L culture. Each form of CYP expressed in the S. typhimurium YG7108 cells catalyzed the oxidation of a representative substrate at an efficient rate. The rates appeared comparable to the reported activities of CYP expressed in human liver microsomes or CYP in other heterologous systems, indicating that the OR was sufficiently expressed to support the catalytic activity of CYP. These S. typhimurium strains may be useful not only for predicting the metabolic activation of promutagens catalyzed by human CYP but also for identifying the CYP form involved. Environ. Mol. Mutagen. 38:329–338, 2001. © 2001 Wiley-Liss, Inc.
REFERENCES
- Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, Tyndale R, Inaba T, Kalow W, Gelboin HV. 1989. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. J Biol Chem 264: 10388–10395.
- Bartsh H, Montesano R. 1984. Relevance of nitrosamines to human cancer. Carcinogenesis 5: 1381–1393.
- Bullas LR, Ryu J. 1983. Salmonella typhimurium LT2 strains which are r−m+ for all three chromosomally located systems of DNA restriction and modification. J Bacteriol 156: 471–474.
- Crespi CL, Penman BW, Leakey JEA, Arlotto MP, Stark A, Parkinson A, Turner T, Steimel DT, Rudo K, Davies RL, Langenbach R. 1990. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis 11: 1293–1300.
- Crespi CL, Langenbach R, Penman B. 1993. Human cell lines, derived from AHH-1 TK+/− human lymphoblasts, genetically engineered for expression of cytochromes P450. Toxicology 82: 89–104.
- Crespi CL, Penman BW, Steimel DT, Smith T, Yang CS, Sutter T. 1997. Development of a human lymphoblastoid cell line constitutively expressing human CYP1B1 cDNA: substrate specificity with model substrates and promutagens. Mutagen 12: 83–89.
- Cresteil T, Monsarrat B, Alvinerie P, Treluyer JM, Vieira I, Wright M. 1994. Taxol metabolism by human liver microsomes: identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54: 386–392.
- Dayer P, Leemann T, Kupfer A, Kronbach T, Meyer UA. 1986. Stereo- and regioselectivity of hepatic oxidation in man-effect of the debrisoquine/sparteine phenotype on bufuralol hydroxylation. Eur J Clin Pharmacol 31: 313–318.
- Dragan YP. 1997. Somatic mutation theory of carcinogenesis. In: GT Bowden, SM Fischer, editors. Comprehensive toxicology: chemical carcinogens and anticarcinogens. Oxford: Elsevier Sciences. p 31–53.
- Gillam EMJ, Guo Z, Ueng YF, Yamazaki H, Cock I, Reilly PEB, Hooper WD, Guengerich FP. 1995. Expression of cytochrome P450 3A5 in Escherichia coli: effects of 5′ modification, purification, spectral characterization, reconstitution conditions, and catalytic activities. Arch Biochem Biophys 317: 374–384.
- Goldstein JA, Faletto MB, Romkes-Sparks M, Sullivan T, Kitareewan S, Raucy JL, Lasker JM, Ghanayem BI. 1994. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 33: 1743–1752.
- Gonzalez FJ, Schmid BJ, Umeno M, Mcbride OW, Hardwick JP, Meyer UA, Gelboin HV, Idle JR. 1988. Human P450PCN1: sequence, chromosome localization, and direct evidence through cDNA expression that P450PCN1 is nifedipine oxidase. DNA 7: 79–86.
- Gorski JC, Hall SD, Jones DR, VandenBranden M, Wrighton SA. 1994. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 47: 1643–1653.
- Greenlee WF, Porland AA. 1978. An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methylcholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin. J Pharmacol Exp Ther 205: 596–605.
- Guengerich FP. 1988. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res 48: 2946–2954.
- Guengerich FP, Shimada T. 1991. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 4: 391–407.
- Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ. 1986. Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261: 5051–5060.
- Hecht SS, Hoffmann D. 1988. Tobacco-specific nitrosamines, an important group of carcinogens in tobacco and tobacco smoke. Carcinogenesis 9: 875–884.
- Hoffmann D, Hecht SS. 1985. Nicotine-derived N-nitrosamines and tobacco-related cancer: current status and future directions. Cancer Res 45: 935–944.
- Ikeya K, Jaiswal AK, Owens RA, Jones JE, Nebert DW, Kimura S. 1989. Human CYP1A2: sequence, gene structure, comparison with the mouse and rat orthologous gene, and differences in liver 1A2 mRNA expression. Mol Endocrinol 3: 1399–1408.
- Imai Y, Ito A, Sato R. 1966. Evidence for biochemically different types of vesicles in the hepatic microsomal fraction. J Biochem 60: 417–428.
- Iwata H, Fujita K, Kushida H, Suzuki A, Konno Y, Nakamura K, Fujino A, Kamataki T. 1998. High catalytic activity of human cytochrome P450 co-expressed with human NADPH-cytochrome P450 reductase in Escherichia coli. Biochem Pharmacol 55: 1315–1325.
- Jaiswal AK, Gonzalez FJ, Nebert DW. 1985. Human P1–450 gene sequence and correlation of mRNA with genetic differences in benzo[a]pyrene metabolism. Nucleic Acids Res 13: 4503–4520.
- Jenkins CM, Waterman MR. 1994. Flavodoxin and NADPH-flavodoxin reductase from Escherichia coli support bovine cytochrome P450c17 hydroxylase activities. J Biol Chem 269: 27401–27408.
- Kato R, Kamataki T, Yamazoe Y. 1983. N-Hydroxylation of carcinogenic and mutagenic aromatic amines. Environ Health Perspect 49: 21–25.
- Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. 1989. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 45: 889–904.
-
Klose TS,
Blaisdell JA,
Goldstein JA.
1999.
Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs.
J Biochem Mol Toxicol
13:
289–295.
10.1002/(SICI)1099-0461(1999)13:6<289::AID-JBT1>3.0.CO;2-N CAS PubMed Web of Science® Google Scholar
- Komori M, Nishio K, Fujitani T, Ohi H, Kitada M, Mima S, Itahashi K, Kamataki T. 1989. Isolation of a new human fetal liver cytochrome P450 cDNA clone: evidence for expression of a limited number of forms of cytochrome P450 in human fetal livers. Arch Biochem Biophys 272: 219–225.
- Komori M, Nishio K, Kitada M, Shiramatsu K, Nuroya K, Soma M, Nagashima K, Kamataki T. 1990. Fetus-specific expression of a form of cytochrome P450 in human liver. Biochemistry 29: 4430–4433.
- Kronbach T, Mathys D, Umeno M, Gonzalez FJ, Meyer UA. 1989. Oxidation of midazolam and triazolam by human liver cytochrome P450IIIA4. Mol Pharmacol 36: 89–96.
- Kupfer A, Desmond P, Patwardhan R, Schenker S, Branch RA. 1984. Mephenytoin hydroxylation deficiency: kinetics after repeated doses. Clin Pharmacol Ther 35: 33–39.
- Kushida H, Fujita K, Suzuki A, Yamada M, Nohmi T, Kamataki T. 2000a. Development of a Salmonella tester strain sensitive to promutagenic N-nitrosamines: expression of recombinant CYP2A6 and human NADPH-cytochrome P450 reductase in S. typhimurium YG7108. Mutat Res 471: 135–143.
- Kushida H, Fujita K, Suzuki A, Yamada M, Endo T, Nohmi T, Kamataki T. 2000b. Metabolic activation of N-alkylnitrosamines in genetically engineered Salmonella typhimurium expressing CYP2E1 or CYP2A6 together with human NADPH-cytochrome P450 reductase. Carcinogenesis 21: 1227–1232.
- Lake BG. 1987. Preparation and characterization of microsomal fractions for studies on xenobiotic metabolism. In: K Snell, B Mullock, editors. Biochemical toxicology: a practical approach. Oxford: IRL Press. p 183–216.
- Lasker JM, Rawcy J, Kubota S, Bloswick BP, Black M, Lieber CS. 1987. Purification and characterization of human liver cytochrome P-450-ALC. Biochem Biophys Res Commun 148: 232–238.
- Leemann BT, Transon C, Dayer P. 1993. Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4′-hydroxylation in human liver. Life Sci 52: 29–34.
- Li Y, Yokoi T, Sasaki M, Hattori K, Katsuki M, Kamataki T. 1996. Perinatal expression and inducibility of human CYP3A7 in C57BL/6N transgenic mice. Biochem Biophys Res Commun 228: 312–317.
- Maron DM, Ames BN. 1983. Revised methods for the Salmonella mutagenicity test. Mutat Res 113: 173–215.
- Meier UT, Dayer P, Male PJ, Kronbach T, Meyer UA. 1985. Mephenytoin hydroxylation polymorphism: characterization of the enzymatic deficiency in liver microsomes of poor metabolizers phenotyped in vivo. Clin Pharmacol Ther 38: 488–494.
- Mirvish SS. 1995. Role of N-nitroso compounds (NOC) and N-nitrosation in etiology of gastric esophageal, nasopharyngeal and bladder cancer and contribution to cancer of known exposures to NOC. Cancer Lett 93: 17–48.
- Nakamura K, Yokoi T, Inoue K, Shimada N, Ohashi N, Kume T, Kamataki T. 1996. CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics 6: 449–457.
- Nelson DR, Koymans L, Kamataki T, Stegeman JJ, Feyereisen R, Waxman DJ, Waterman MR, Gotoh O, Coon MJ, Estabrook RW, Gunsalus IC, Nebert DW. 1996. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6: 1–41.
- Ohgiya S, Komori M, Ohi H, Shiramatsu K, Shinriki N, Kamataki T. 1992. Six-base deletion occurring in messages of human cytochrome P-450 in the CYP2C subfamily results in reduction of tolbutamide hydroxylase activity. Biochem Int 27: 1073–1081.
- Omura T, Sato R. 1964. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: 2370–2378.
- Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M. 1996. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26: 681–693.
- Parkinson A. 1996. Biotransformation of xenobiotics. In: CD Klassen, editor. Casarett and Doull's toxicology: the basic science of poisons. New York: McGraw-Hill. p 113–186.
- Pearce R, Greenway D, Parkinson A. 1992. Species differences and interindividual variation in liver microsomal cytochrome P450 2A enzymes: effects on coumarin, dicumarol, and testosterone oxidation. Arch Biochem Biophys 298: 211–225.
- Peterson J, Ebel RE, O'Keeffe DH, Matsubara T, Estabrook RW. 1976. Temperature dependence of cytochrome P-450 reduction. J Biol Chem 251: 4010–4016.
- Phillips AH, Langton RG. 1962. Hepatic triphosphopyridine nucleotide (TPN)-cytochrome c reductase: isolation, characterization and kinetic studies. J Biol Chem 237: 2370–2378.
- Pilot III HC, Dragan YP. 1996. Chemical carcinogenesis. In: CD Klassen, editor. Casarett and Doull's toxicology: the basic science of poisons. New York: McGraw-Hill. p 201–267.
- Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. 1994. Selective biotransformation of taxol to 6α-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 54: 5543–5546.
- Romkes M, Faletto MB, Blaisdell JA, Raucy JL, Goldstein JA. 1991. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry 30: 3247–3255.
- Sandhu P, Baba T, Guengerich FP. 1993. Expression of modified cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Arch Biochem Biophys 306: 443–450.
- Shimada T, Misono KS, Guengerich FP. 1986. Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. J Biol Chem 261: 909–921.
- Shimada T, Yun CH, Yamazaki H, Gautier JC, Beaune PH, Guengerich FP. 1992. Characterization of human lung microsomal cytochrome P-450 1A1 and its role in the oxidation of chemical carcinogens. Mol Pharmacol 41: 856–864.
- Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414–423.
- Shimada T, Wunsch RM, Hanna IH, Sutter TR, Guengerich FP, Gillam EMJ. 1998. Recombinant human cytochrome P450 1B1 expression in Escherichia coli. Arch Biochem Biophys 357: 111–120.
- Shimada T, Tsumura F, Yamazaki H. 1999. Prediction of human liver microsomal oxidation of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos 27: 1274–1280.
- Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosokawa M, Chiba K. 2000. CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10: 95–104.
- Tang YM, Wo YY, Stewart J, Hawkins AL, Griffin CA, Sutter TR, Greenlee WF. 1996. Isolation and characterization of the human cytochrome P450 CYP1B1 gene. J Biol Chem 271: 28324–28330.
- Taniguchi H, Imai Y, Iyanagi T, Sato R. 1979. Interaction between NADPH-cytochrome P-450 reductase and cytochrome P-450 in the membrane of phosphatidylcholine vesicles. Biochem Biophys Acta 550: 341–356.
- Umeno M, McBride OW, Yang CS, Gelboin HV, Gonzalez FJ. 1988. Human ethanol-inducible P450IIE1: complete gene sequence, promoter characterization, chromosome mapping, and cDNA-directed expression. Biochemistry 27: 9006–9013.
- Vermeulen NPE. 1996. Role of metabolism in chemical toxicity. In: C Ioannides, editor. Cytochromes P450: metabolic and toxicological aspects. New York: CRC Press. p 29–53.
- Wrighton SA, Thomas PE, Ryan DE, Levin W. 1987. Purification and characterization of ethanol-inducible human hepatic cytochrome P-450HLj. Arch Biochem Biophys 258: 292–297.
- Wynder EL, Hoffmann D. 1994. Smoking and lung cancer: scientific challenges and opportunities. Cancer Res 54: 5284–5295.
- Yamada M, Sedgwick B, Sofuni T, Nohmi T. 1995. Construction and characterization of mutants of Salmonella typhimurium deficient in DNA repair of O6-methylguanine. J Bacteriol 177: 1511–1519.
- Yamano S, Tatsuno J, Gonzalez FJ. 1990. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 29: 1322–1329.
- Yasumori T, Murayama N, Yamazoe Y, Abe A, Nogi Y, Fukasawa T, Kato R. 1989. Expression of a human P-450IIC gene in yeast cells using galactose-inducible expression system. Mol Pharmacol 35: 443–449.
- Yun CH, Shimada T, Guengerich FP. 1991. Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol 40: 679–685.